This market resolves to Yes if there is credible evidence by April 2027 that the expansion of Cardinal Health's Actinium-225 (Ac-225) production has successfully eased supply constraints for targeted alpha therapies. Confirmation can come from industry reports, announcements from Cardinal Health, or independent healthcare analyses indicating a reduction in supply issues.